Adicet Bio, Inc.

Symbol: ACET

NASDAQ

1.63

USD

Market price today

  • -0.4961

    P/E Ratio

  • -0.0196

    PEG Ratio

  • 133.94M

    MRK Cap

  • 0.00%

    DIV Yield

Adicet Bio, Inc. (ACET) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-0.68%

Return on Equity

-1.69%

Return on Capital Employed

-0.81%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Chen Schor BA, CPA, M.B.A.
Full-time employees:143
City:Boston
Address:200 Clarendon Street
IPO:2018-01-26
CIK:0001720580

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Return on Investments

The company's asset efficiency, represented by a robust -0.682% return, is a testament to Adicet Bio, Inc.'s adeptness in optimizing resource deployment. Adicet Bio, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.689%. Furthermore, the proficiency of Adicet Bio, Inc. in capital utilization is underscored by a remarkable -0.809% return on capital employed.

Stock Prices

Adicet Bio, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.63, while its low point bottomed out at $1.51. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Adicet Bio, Inc.'s stock market.

Liquidity Ratios

Analyzing ACET liquidity ratios reveals its financial health of the firm. The current ratio of 841.35% gauges short-term asset coverage for liabilities. The quick ratio (828.08%) assesses immediate liquidity, while the cash ratio (828.08%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio841.35%
Quick Ratio828.08%
Cash Ratio828.08%

Profitability Ratios

The effective tax rate stands at 1.06%, revealing its tax efficiency. The net income per EBT, 99.12%, and the EBT per EBIT, 93.83%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Effective Tax Rate1.06%
Net Income per EBT99.12%
EBT per EBIT93.83%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 8.41, it details the span from stock purchase to revenue. The 8 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding828
Days of Payables Outstanding118
Payables Turnover3.10

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -2.18, and free cash flow per share, -2.28, depict cash generation on a per-share basis. The cash per share value, 3.71, showcases liquidity position.

cards.indicatorcards.value
Operating Cash Flow per Share-2.18
Free Cash Flow per Share-2.28
Cash per Share3.71
Free Cash Flow to Operating Cash Flow Ratio1.05
Cash Flow Coverage Ratio-4.48
Short Term Coverage Ratio-29.10
Capital Expenditure Coverage Ratio-20.99
Dividend Paid and Capex Coverage Ratio-20.99

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 10.09%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.12, we discern the balance between debt and equity financing. The long-term debt to capitalization, 9.42%, and total debt to capitalization, 10.95%, ratios shed light on its capital structure. An interest coverage of -6335.00 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio10.09%
Debt Equity Ratio0.12
Long Term Debt to Capitalization9.42%
Total Debt to Capitalization10.95%
Interest Coverage-6335.00
Cash Flow to Debt Ratio-4.48
Company Equity Multiplier1.22

Per Share Data

Net income per share, -3.31, reflects the portion of profit attributed to each share. The book value per share, 3.95, represents the net asset value distributed per share, while the tangible book value per share, 3.95, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-3.31
Book Value Per Share3.95
Tangible Book Value Per Share3.95
Shareholders Equity Per Share3.95
Interest Debt Per Share0.49
Capex Per Share-0.10

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -100.00%, indicates top-line expansion, while the gross profit growth, -130.52%, reveals profitability trends. EBIT growth, -82.73%, and operating income growth, -82.73%, offer insights into operational profitability progression. The net income growth, -112.83%, showcases bottom-line expansion, and the EPS growth, -103.07%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-100.00%
Gross Profit Growth-130.52%
EBIT Growth-82.73%
Operating Income Growth-82.73%
Net Income Growth-112.83%
EPS Growth-103.07%
EPS Diluted Growth-103.07%
Weighted Average Shares Growth4.78%
Weighted Average Shares Diluted Growth4.78%
Operating Cash Flow Growth-109.35%
Free Cash Flow Growth-59.52%
10-Year Revenue Growth per Share-100.00%
5-Year Revenue Growth per Share-100.00%
3-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share-331.18%
5-Year Operating CF Growth per Share-134.61%
3-Year Operating CF Growth per Share61.64%
10-Year Net Income Growth per Share-501.53%
5-Year Net Income Growth per Share-598.22%
3-Year Net Income Growth per Share33.85%
10-Year Shareholders Equity Growth per Share-54.21%
5-Year Shareholders Equity Growth per Share-25.67%
3-Year Shareholders Equity Growth per Share127.22%
Receivables Growth-100.00%
Inventory Growth-100.00%
Asset Growth-37.31%
Book Value per Share Growth168.21%
Debt Growth-0.47%
R&D Expense Growth48.84%
SGA Expenses Growth-22.29%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -57,436,854.55, captures the company's total value, considering both debt and equity. Income quality, 0.66, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value-57,436,854.55
Income Quality0.66
Capex to Operating Cash Flow4.76%
Capex to Depreciation-73.20%
Graham Number17.17
Return on Tangible Assets-68.82%
Graham Net Net2.85
Working Capital142,985,000
Tangible Asset Value170,175,000
Net Current Asset Value125,152,000
Average Receivables217,500
Average Payables3,514,500
Average Inventory1,283,500
Days Payables Outstanding157
ROIC-69.38%
ROE-0.84%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.41, and the price to book ratio, 0.41, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -1.36, and price to operating cash flows, -0.75, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.41
Price to Book Ratio0.41
Price Cash Flow Ratio-0.75
Price Earnings to Growth Ratio-0.02
Enterprise Value Multiple-2.27
Price Fair Value0.41
Price to Operating Cash Flow Ratio-0.75
Price to Free Cash Flows Ratio-1.36
Price to Tangible Book Ratio0.48
Enterprise Value Over EBITDA0.45
EV to Operating Cash Flow0.61
Earnings Yield-175.36%
Free Cash Flow Yield-120.69%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Adicet Bio, Inc. (ACET) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.496 in 2024.

What is the ticker symbol of Adicet Bio, Inc. stock?

The ticker symbol of Adicet Bio, Inc. stock is ACET.

What is company IPO date?

IPO date of Adicet Bio, Inc. is 2018-01-26.

What is company current share price?

Current share price is 1.630 USD.

What is stock market cap today?

The market cap of stock today is 133936448.000.

What is PEG ratio in 2024?

The current -0.020 is -0.020 in 2024.

What is the number of employees in 2024?

In 2024 the company has 143.